Research Progress of CD47-SIRP<i>α</i> in Esophageal Cancer

食管癌的发生、发展与许多因素有关，其中免疫系统发挥重要作用。CD47-SIRPα是PD-1/PD-L1，CTLA4之后的又一个免疫检查点，已经证明在多种血液系统肿瘤与实体瘤中高表达，通过产生抑制性信号阻止巨噬细胞吞噬癌细胞。本文针对其在食管癌中的表达、与患者预后的关系、免疫治疗进行综述，通过本文的阐述，食管癌中的CD47-SIRPα同样是高表达，高CD47或高SIRPα都是导致食管癌患者预后不良的因素，抗CD47抗体与人源性食管癌细胞、人源性食管癌裸鼠模型有一定的结合活性。The occurrence and development of esophageal cancer are related to many factors, among which the immune system plays an important role. CD47-SIRPα is another immune checkpoint after PD-1/PD-L1 and CTLA4. It has been proved to be highly expressed in various hematological malignancies and solid tumors. It inhibits macrophage phagocytosis of cancer cells by generating inhibitory signals. This article reviews the expression of CD47-SIRPα in esophageal cancer, its relationship with the prognosis of patients, and immunotherapy. Through the elaboration of this article, CD47-SIRPα is also highly expressed in esophageal cancer. High CD47 or high SIRPα are both factors contributing to poor prognosis of patients with esophageal cancer, Anti-CD47 antibodies have certain binding activity with human esophageal cancer cells and human esophageal cancer nude mouse models.